Evidence map›Paper›PMID 38880415›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2024

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

Kevin X Liu, Sherif G Shaaban, Jie Jane Chen, Rochelle Bagatell, Benjamin J Lerman, Paul J Catalano, Steven G DuBois, Suzanne Shusterman, Myrsini Ioakeim-Ioannidou, Torunn I Yock and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Molecular principles underlying aggressive cancers.Signal transduction and targeted therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Kevin X LiuDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Sherif G ShaabanDepartment of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD, USA.
Jie Jane ChenDepartment of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA, USA; Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rochelle BagatellDepartment of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Benjamin J LermanDepartment of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA.
Paul J CatalanoDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Steven G DuBoisDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Suzanne ShustermanDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Myrsini Ioakeim-IoannidouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Torunn I YockDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Robert C ShambergerDepartment of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Peter MatteiDepartment of Surgery, University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Lan VuDepartment of Surgery, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA.
Hesham ElhalawaniDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Kathryn E DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA.
Kieuhoa T VoDepartment of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA.
Mary S HuangDepartment of Pediatric Oncology, Massachusetts General Hospital, Boston, MA, USA.
Alison M FriedmannDepartment of Pediatric Oncology, Massachusetts General Hospital, Boston, MA, USA.
Lisa R DillerDepartment of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Karen J MarcusDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Shannon M MacDonaldDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Stephanie A TerezakisDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA, USA.
Christine E Hill-KayserDepartment of Radiation Oncology, University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Daphne A Haas-KoganDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: dhaas-kogan@bwh.harvard.edu.

Funding

Shared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI DAPHNE A. HAAS-KOGAN · 2023 to 2026
$8.1M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
Optimizing 131I-mIBG Therapy for Children with Advanced NeuroblastomaR01CA172067 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBOIS, STEVEN · 2013 to 2017
$1.6M
NCI NIH HHS L40 CA264321NCI NIH HHS R01 CA172067NCI NIH HHS T32 CA128583NCI NIH HHS T32 CA151022NCI NIH HHS U54 CA274516
6 · The paper itself

Abstract

backgroundPrognosis for patients with high-risk neuroblastoma (HR-NBL) is guarded despite aggressive therapy, and few studies have characterized outcomes after radiotherapy in relation to radiation treatment fields.

methodsMulti-institutional retrospective cohort of 293 patients with HR-NBL who received autologous stem cell transplant (ASCT) and EBRT between 1997-2021. LRR was defined as recurrence at the primary site or within one nodal echelon beyond disease present at diagnosis. Follow-up was defined from the end of EBRT. Event-free survival (EFS) and OS were analyzed by Kaplan-Meier method. Cumulative incidence of locoregional progression (CILP) was analyzed using competing risks of distant-only relapse and death with Gray's test.

resultsMedian follow-up was 7.0 years (range: 0.01-22.4). Five-year CILP, EFS, and OS were 11.9 %, 65.2 %, and 77.5 %, respectively. Of the 31 patients with LRR and imaging review, 15 (48.4 %) had in-field recurrences (>12 Gy), 6 (19.4 %) had marginal failures (≤12 Gy), and 10 (32.3 %) had both in-field and marginal recurrences. No patients receiving total body irradiation (12 Gy) experienced marginal-only failures (p = 0.069). On multivariable analyses, MYCN amplification had higher risk of LRR (HR: 2.42, 95 % CI: 1.06-5.50, p = 0.035) and post-consolidation isotretinoin and anti-GD2 antibody therapy (HR: 0.42, 95 % CI: 0.19-0.94, p = 0.035) had lower risk of LRR.

conclusionsDespite EBRT, LRR remains a contributor to treatment failure in HR-NBL with approximately half of LRRs including a component of marginal failure. Future prospective studies are needed to explore whether radiation fields and doses should be defined based on molecular features such as MYCN amplification, and/or response to chemotherapy.

Indexed as

Neoplasm Recurrence, LocalNeuroblastomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleRadiotherapy DosageRetrospective StudiesAutologous stem cell therapyDinutuximabMYCN amplificationPhoton radiotherapyProton radiotherapyTotal body irradiation

Identifiers

PMID38880415
PMCPMC12255944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.